Abstract
Low-Dose Ketamine in the Rapid Relief of hyperalgesic vaso-occlusive Bone Crises in Sickle Cell Disease Patients
Highlights
Worldwide, sickle cell disease (SCD) represents the most common genetic disorder of haemoglobin and disproportionately affects Africa 1-3
The reduction of pain intensity observed on the VAS60 coupled with “a pain relief respond” at the 60th minute of treatment helped deduce a visual analogue scale (VAS) sensibility of 100%, a specificity of 52.9%, a positive predictive value of 65.2% for the endpoint “patient relief” and a negative predictive value of zero (Table 4)
In blocking NMDA receptors of glutamate, ketamine reduces central sensitisation induced by opioids and tissue lesions, with resultant inhibition of hyperalgesia leading to a reduction in pain intensity and minute consumption of analgesics
Summary
Sickle cell disease (SCD) represents the most common genetic disorder of haemoglobin and disproportionately affects Africa 1-3. This disease is associated with a profound clinical polymorphism entailing three main categories of clinical presentations; chronic haemolytic anaemia with episodes of acute exacerbation, vaso-occlusive crises and an increased susceptibility to bacterial infections 1,3,4. We conducted this study to assess the quality of analgesia induced by low doses of ketamine in the management of hyperalgesic vaso-occlusive bone crises in SCD patients. The aim of this study was to assess the quality of analgesia procured by low doses of ketamine in the management of hyperalgesic vaso-occlusive bone crises in SCD patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
